ACETIC ACID (excluding its salts and derivatives) and preparations containing
more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.
ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACONITUM spp. for therapeutic use in adults:
(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or
(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.
ALOXIPRIN.
AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN except:
(a) when included in Schedule 4, 5 or 6;
(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
(i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
(ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
(ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg
or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels.
ATROPA BELLADONNA (belladonna):
(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
Schedule Sch 2 - Poisons Standard 2010 | Zoe
(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ATROPINE (excluding atropine methonitrate) for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
AZELAIC ACID in dermal preparations.
AZELASTINE in preparations for nasal use.
BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
BENZOCAINE in preparations for topical use other than eye drops:
(a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide except in preparations containing 5 per cent or less of benzoyl peroxide.
BENZYDAMINE in preparations for topical use, except in preparations for dermal use.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:
(a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or
BROMHEXINE.
BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use.
CHLOPHEDIANOL.
CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol except in preparations containing 0.5 per cent or less of chlorbutol.
CHLOROFORM in preparations for therapeutic use except:
(b) in preparations containing 0.5 per cent or less of chloroform.
CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
CICLOPIROX in preparations for dermal use and for application to the nails containing 2 per cent or less of ciclopirox except in preparations for the treatment of tinea pedis.
CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.
CINNAMEDRINE.
CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
CODEINE in preparations for the treatment of coughs and colds when:
(a) not combined with any other opiate substance;
(b) compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:
(i) in divided preparations containing 10 mg or less of codeine per dosage unit; or
(ii) in undivided preparations containing 0.25 per cent or less of codeine;
(c) labelled with a recommended daily dose not exceeding 60 mg of codeine; and
(d) in packs containing not more than 6 days' supply at the maximum dose recommended on the label.
CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.
DATURA spp. for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except when separately specified in these Schedules.
DATURA STRAMONIUM (stramonium) for oral use when:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DATURA TATULA (stramonium) for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of Delphinium staphisagria.
DESLORATADINE in preparations for oral use.
DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac.
DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:
(a) containing 5 mg or less of dihydrocodeine per dosage unit;
(b) packed in blister or strip packaging or in a container with a child-resistant closure;
(c) enclosed in primary packs containing 25 or less dosage units; and
(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.
DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
DUBOISIA LEICHHARDTII for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
DUBOISIA MYOPOROIDES for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
ETAFEDRINE.
ETHER for therapeutic use except:
(b) in preparations containing 10 per cent or less of ether.
ETHYLMORPHINE when:
(a) compounded with one or more other therapeutically active substances:
(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
(ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine; and
(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use.
FLUORIDES for human use:
(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or
(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container SCHEDULE 2 – continued
with a child-resistant closure:
(i) for therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels except in preparations containing 220 mg/kg or less
of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
(ii) for non-therapeutic use when labelled with warnings to the following effect:
(B) Do not use [this product/name of product] in children six years of age or less,
except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:
(B) Do not use [this product/name of product] in children six years of age or less,
except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in preparations for topical oral use when:
(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or
(b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.
FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use except:
(b) in preparations containing 500 micrograms or less of folic acid
per recommended daily dose.
FOLINIC ACID for human therapeutic use except:
(b) in preparations containing 500 micrograms or less of folinic acid
per recommended daily dose.
† FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b) in other preparations containing 0.2 per cent or less of free formaldehyde.
GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.
GELSEMIUM SEMPERVIRENS.
GLUTARALDEHYDE for human therapeutic use.
HEXACHLOROPHANE in preparations for human use containing 3 per cent or less
of hexachlorophane except:
(a) in preparations containing 0.75 per cent or less of hexachlorophane; or
(b) in preparations for use on infants, as specified in Schedule 4.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:
(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:
(i) in undivided preparations in packs of 35 g or less; or
(ii) in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone except in hair preparations containing 0.3 per cent or less of hydroquinone.
8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1 per cent or less of such substances.
HYOSCINE (excluding hyoscine butylbromide):
(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.
HYOSCYAMINE:
(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
(i) in undivided preparations containing 0.03 per cent or less of total solanaceous
alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:
(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:
(a) in liquid preparations when sold in the manufacturer’s original pack containing 4 grams or less of ibuprofen; or
(b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:
(i) as the only therapeutically active constituent other than an effervescent agent;
(ii) packed in blister or strip packaging or in a container with a child-resistant closure;
(iii) in a primary pack containing not more than 25 dosage units;
(iv) not labelled for the treatment of children 6 years of age or less; and
(v) compliant with the requirements of the Required Advisory Statements for Medicine Labels.
INDANAZOLINE.
INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.
IODINE:
(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
(b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),
except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use except:
(b) when labelled with a recommended daily dose of 24 mg or less of iron:
(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
(ii) in divided preparations:
(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
(B) containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.
KETOCONAZOLE in preparations for dermal use except:
(a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.
LEVOCABASTINE in topical eye or nasal preparations.
LIGNOCAINE in preparations for topical use other than eye drops:
(a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.
LITHIUM in preparations for dermal use containing 1 per cent or less of lithium except:
(a) when present as an excipient at 0.25 per cent or less of lithium; or
(b) in preparations containing 0.01 per cent or less of lithium.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less.
LORATADINE in preparations for oral use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome.
MERCURY for external use in preparations containing 0.5 per cent or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1 per cent or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
NICLOSAMIDE for human therapeutic use.
NICOTINE for use as an aid in withdrawal from tobacco smoking in preparations for inhalation.
NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
PAPAVERINE except when included in Schedule 4.
PARACETAMOL for therapeutic use except:
(b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or
guaiphenesin or when combined with effervescent agents) when:
(i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;
(ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(iii) not labelled for the treatment of children 6 years of age or less; and
(iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or
(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:
(ii) in a primary pack containing not more than 25 tablets or capsules;
(iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(iv) not labelled for the treatment of children 6 years of age or less; and
(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.
† PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b) in other preparations containing 0.2 per cent or less of free formaldehyde.
PENCICLOVIR for external use for the treatment of herpes labialis.
PHEDRAZINE.
PHENAZONE for human external use.
PHENIRAMINE:
(a) in eye drops; or
(b) when combined with one or more other therapeutically active substances in oral preparations when:
(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:
(b) in preparations for external use containing 3 per cent or less of such substances.
PHENYLEPHRINE except:
(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
(c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.
PHOLCODINE:
(a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.
PIPERAZINE for human therapeutic use.
PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or less of potassium chlorate.
PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
(b) when combined with one or more other therapeutically active substances when:
(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or
pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.
RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply except in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SELENIUM in preparations for human therapeutic use except:
(a) for topical use containing 3.5 per cent or less of selenium sulfide;
(b) when included in Schedule 4; or
(c) for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use except:
(a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or
(b) in other preparations containing 1 per cent or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1 per cent or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACHLOROETHYLENE for human therapeutic use.
TETRAHYDROZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.